129 related articles for article (PubMed ID: 35772003)
21. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
Warsame R; LaPlant B; Kumar SK; Laumann K; Perez Burbano G; Buadi FK; Gertz MA; Kyle RA; Lacy MQ; Dingli D; Leung N; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves WI; Kourelis T; Lust J; Russell SJ; Zeldenrust S; Lin Y; Muchtar E; Go RS; Vincent Rajkumar S; Dispenzieri A
Blood Cancer J; 2020 Jan; 10(1):4. PubMed ID: 31913261
[TBL] [Abstract][Full Text] [Related]
22. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
[No Abstract] [Full Text] [Related]
23. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar E; Dispenzieri A; Wisniowski B; Palladini G; Milani P; Merlini G; Schönland S; Veelken K; Hegenbart U; Geyer SM; Kumar SK; Kastritis E; Dimopoulos MA; Liedtke M; Witteles R; Sanchorawala V; Szalat R; Landau H; Petrlik E; Lentzsch S; Coltoff A; Bladé J; Cibeira MT; Cohen O; Foard D; Wechalekar A; Gertz MA
J Clin Oncol; 2023 Mar; 41(7):1393-1403. PubMed ID: 36215675
[TBL] [Abstract][Full Text] [Related]
24. The Real-World Data on Patients With Cardiac Stage IIIb AL Amyloidosis.
Hong Y; Guo J; Chen W; Zhao L; Liu Z; Huang X
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38806310
[TBL] [Abstract][Full Text] [Related]
25. Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.
Kastritis E; Misra A; Gurskyte L; Kroi F; Verhoek A; Vermeulen J; Ammann E; Lam A; Cote S; Wechalekar AD
Hematology; 2023 Dec; 28(1):2157581. PubMed ID: 36607151
[TBL] [Abstract][Full Text] [Related]
26. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
27. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
29. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
30. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
31. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
32. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
34. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
[TBL] [Abstract][Full Text] [Related]
35. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
37. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E; Fotiou D; Theodorakakou F; Dialoupi I; Migkou M; Roussou M; Karatrasoglou EA; Tselegkidi MI; Ntalianis A; Kanellias N; Eleutherakis-Papaiakovou E; Ntanasis-Stathopoulos I; Gakiopoulou C; Papanikolaou A; Papathoma A; Spyropoulou-Vlachou M; Psimenou E; Stamatelopoulos K; Gavriatopoulou M; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):3-11. PubMed ID: 32713209
[TBL] [Abstract][Full Text] [Related]
38. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Milani P; Sharpley F; Schönland SO; Basset M; Mahmood S; Nuvolone M; Kimmich C; Foli A; Sachchithanantham S; Merlini G; Wechalekar A; Palladini G; Hegenbart U
Amyloid; 2020 Dec; 27(4):231-236. PubMed ID: 32449385
[TBL] [Abstract][Full Text] [Related]
39. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
40. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL; Warsame R; Gertz MA; Buadi FK; Lacy MQ; Kumar SK; Dingli D; Zeldenrust SR; Leung N; Hayman SR; Kapoor P; Gonsalves WI; Kourelis TV; Russell S; Go RS; Hobbs MA; Fonder AL; Rajkumar SV; Dispenzieri A
Blood; 2017 Sep; 130(13):1578-1584. PubMed ID: 28807981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
